Abstract
The matrix metalloproteinases, MMP-2 and MMP-9, are capable of degrading components of the basement membrane, a vital barrier breached during the progression of colorectal cancer. The regulation of MMP-2 activation and subsequent targets is vital to understanding the metastatic process. MMP-2 was not expressed by colorectal cancer cells (C170 and C170HM2) in vitro but by stromal fibroblasts (46BR.1GI). There was induction of this MMP upon transwell co-cultivation of the colon cancer cells with the fibroblasts but in vivo growth did not lead to a similar increase in the metastatic tumour cells (C170HM2), MMP-2 again being attributed to the stromal cells. MMP-2 mRNA was overexpressed in human colorectal tumours compared to normal colorectal tissue, which correlated with Dukes’ stage and immunolocalized to the stromal compartment of the tumour tissue. The active form of the MMP-2 enzyme was also present in the colorectal tumour tissue (7/8) but essentially absent in all normal colon samples examined (1/8). MMP-2 activation was not related to an increase in MT-1-MMP mRNA or a decrease in the specific inhibitor TIMP-2 in human tissue. There was however an increase in MMP-2/TIMP-2 ratio in tumour compared to normal. MMP-9, a target of active MMP-2, was present in the metastatic cell line but expression was down-regulated in the tumour cells in vivo, gelatin analysis revealed that MMP-9 was almost entirely attributable to the murine host, confirmed by PCR. There was no increase in mRNA for MMP-9 or its specific inhibitor TIMP-1 in colorectal tumour tissue compared to normal, MMP-9 protein localized to the inflammatory infiltrate. Fibroblast cells may provide malignant epithelial cells with a ready source of enzyme which is crucial to the metastatic process. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Birkedal-Hanson H, Moore W, Bodden M, Windsor L, Birkedal-Hanson B, Decarlo A and Engler J (1993) Matrix metalloproteinases a review. Crit Rev Oral Biol Med 4: 197–250
Biswas C, Zhang Y, DeCastro R, Guo H, Nakamura T, Kataoka H and Nabeshima K (1995) The human tumour cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res 55: 434–439
Brown PD, Levy A, Margulies I, Liotta L and Stetler-Stevenson W (1990) Independent expression and cellular processing of Mr 72,000 type-IV collagenase and interstitial collagenase in human tumorigenic cell lines. Cancer Res 50: 6184–6191
Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T, Neal D, Thomas D, Hanby A and Balkwill F (1993) Levels of matrix metalloproteases in bladder cancer correlate with tumour grade and invasion. Cancer Res 53: 5365–5369
D’Errico A, Garbisa S, Liotta L, Astronovo V, Stetler-Stevenson W and Grigioni W (1991) Augmentation of type IV collagenase, laminin receptor and Ki67 proliferation antigen associated with human colon, gastric and breast carcinoma progression. Mod Pathol 4: 239–246
Durrant LG, Robins RA, Pimm MV, Perkins AC, Armitage NC, Hardcastle JD and Baldwin RW (1986) Antigenicity of newly established colorectal carcinoma cell lines. Br J Cancer 53: 37–45
Ellerbroek SM, Fishman DA, Kearns AS, Bafetti LM and Stack MS (1999) Ovarian carcinoma regulation of Matrix metalloproteinase-2 and membrane type 1 matrix metalloproteinase through β1 integrin. Cancer Res 59: 1635–1641
Fridman R, Toth M, Pena D and Mobashery S (1995) Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res 55: 2548–2555
Harris ED Jr (1990) Rheumatoid arthritis. Pathophysiology and implications for therapy. New Engl J Med 322: 1277–1289
Heppner KJ, Matrisian LM, Jensen RA and Rodgers WH (1996) Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol 149: 273–282
Hewitt R, Leach I, Powe D, Clark I, Cawston T and Turner D (1991) Distribution of collagenase and tissue inhibitor of metalloproteinases (TIMP) in colorectal tumors. Int J Cancer 49: 666–672
Hyuga S, Nishikawa Y, Sakata K, Tanaka H, Yamagata S, Sugita K, Saga S, Matsuyama M and Shimizu S (1994) Autocrine factor enhancing the secretion of Mr 95,000 gelatinase (Matrix Metalloproteinase 9) in serum free medium conditioned with murine metastatic colon carcinoma cells. Cancer Res 54: 3611–3616
Lehti K, Lohi J, Valtnan H and Keski-Oja J (1998) Proteolytic processing of membrane-type-1 matrix metalloproteinase is associated with gelatinase activation at the cell surface. Biochem J 334: 345–353
Lengyel E, Gum R, Juarez J, Clayman G, Seiki M, Sato H and Boyd D (1995) Induction of Mr 92,000 Type IV collagenase expression in a squamous cell carcinoma cell line by fibroblasts. Cancer Res 55: 963–967
Liabakk N, Talbot I, Smith RA, Wilkinson K and Balkwill F (1996) Matrix metalloproteinases2 (MMP-2) and matrix metalloproteinase 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res 56: 190–196
Masuda H and Aoki H (1999) Host expression of Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in normal colon tissue affects metastatic potential of colorectal cancer. Dis Colon Rectum 42: 393–397
Masure S, Nys G, Fiften P, Van Damme J and Opdenakker G (1993) Mouse Gelatinase B: cDNA cloning, regulation of expression and glycosylation in WEHI-3 macrophages and gene organisation. Eur J Biochem 218: 129–141
McDonnell S, Chaudhry V, Mansilla-Soto J, Zeng Z-S, Shu WP and Guillem JG (1999) Metastatic and non-metastatic colorectal cancer (CRC) cells induce host metalloproteinase production in vivo. Clin Exp Metas 17: 341–349
Noel A, Polette M, Lewalle J-M, Munaut C, Edmonard HP, Birembaut P and Foidart J-M (1994) Co-ordinate enhancement of gelatinase A mRNA and activity levels in human fibroblasts in response to breast-adenocarcinoma cells. Int J Cancer 56: 331–336
Ornstein DL, MacNab J and Cohn KH (1999) Evidence for tumour-host co-operation in regulating MMP-2 expression in human colon cancer. Clin Exp Metas 17: 202–212
Page RC (1991) The role of inflammatory mediators in the pathogenesis of periodontal disease. J Periodont Res 26: 230–242
Parsons SL, Watson SA, Collins HM, Griffin NR, Clarke PA and Steele RJC (1998) Gelatinase (MMP-2 and –9) expression in gastrointestinal malignancy. Br J Cancer 78: 1495–1502
Pender S, Tickle S, Docherty A, Howie D, Wathen N and MacDonald T (1997) A major role for matrix metalloproteinases in T-Cell injury in the gut. J Immunol 158: 1582–1590
Polette M, Gilles C, Marchand V, Seiki M, Tournier JM and Birembaut P (1997) Induction of membrane-type matrix metalloproteinase 1 (MTl-MMP) expression in human fibroblasts by breast adenocarcinoma cells. Clin Exp Metas 15: 157–163
Poulsom R, Pignatelli M, Stetler-Stevenson WG, Liotta LA, Wright PA, Jeffery RE, Longcroft JM, Rodgers L and Stamp GWH (1992) Stromal expression of 72kDa Type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am J Pathol 141: 389–396
Pyke C, Ralfkiaer E, Tryggvason K and Dano K (1993) Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am J Pathol 142: 359–365
Saito K, Takeha S, Shiba K, Matsuno S, Sorsa T, Nagura H and Ohtani H (2000) Clinicopathologic significance of urokinase receptor-and MMP-9-positive stromal cells in human colorectal cancer: functional multiplicity of matrix degradation on hematogenous metastasis. Int J Cancer 86: 24–29
Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E and Seiki M (1994) A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370: 61–65
Segain JP, Harb J, Gregoire M, Meflah K and Menanteau J (1996) Induction of fibroblast gelatinase B expression by direct contact with cell lines derived from primary tumour but not metastases. Cancer Res 56: 5506–5512
Shimizu S, Nishikawa Y, Kuroda K, Takagi S, Kozaki K, Hyuga S, Saga S and Matsuyama M (1996) Involvement of Transforming growth factor β1 in autocrine enhancement of gelatinase B secretion by murine metastatic colon carcinoma cells. Cancer Res 56: 3366–3370
Stanton H, Gavrilovic J, Atkinson SJ, d’Ortho MP, Yamada KM, Zardi L and Murphy G (1998) The activation of proMMP-2 (gelatinase A) by HT1080 cells is promoted by culture on a fibronectin substrate and is concomitant with an increase in processing of MT-1-MMP (MMP-14) to a 45kDa form. J Cell Sci 111: 2789–2798
Stetler-Stevenson WG, Liotta LA and Kleiner DE (1993) Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J 7: 1434–1441
Watson SA, Morris TM, Crosbee DM and Hardcastle JD (1993) A new hepatic invasive human colo-rectal xenograft model. Eur J Cancer 29: 1740–1745
Wells GMA, Catlin G, Cossins JA, Mangan M, Ward GA, Miller KM and Clements JM (1996) Quantitation of Matrix Metalloproteinases in cultured rat astrocytes using the polymerase chain reaction with a multicompetitor cDNA standard. Glia 18: 332–340
Westermarck J and Kahari VM (1999) Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 13: 781–792
Zeng ZS and Guillem JG (1995) Distinct pattern of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase 1 mRNA expression in human colorectal cancer and liver metastases. Br J Cancer 72: 575–582
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Collins, H., Morris, T. & Watson, S. Spectrum of matrix metalloproteinase expression in primary and metastatic colon cancer: relationship to the tissue inhibitors of metalloproteinases and membrane type-1-matrix metalloproteinase. Br J Cancer 84, 1664–1670 (2001). https://doi.org/10.1054/bjoc.2001.1831
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.1831
Keywords
This article is cited by
-
RelB plays an oncogenic role and conveys chemo-resistance to DLD-1 colon cancer cells
Cancer Cell International (2018)
-
TRIM14 promotes colorectal cancer cell migration and invasion through the SPHK1/STAT3 pathway
Cancer Cell International (2018)
-
Assessing the value of matrix metalloproteinase 9 (MMP9) in improving the appropriateness of referrals for colorectal cancer
British Journal of Cancer (2013)
-
Serum matrix metalloproteinase 9 and colorectal neoplasia: a community-based evaluation of a potential diagnostic test
British Journal of Cancer (2012)
-
JNK suppression is essential for 17β-Estradiol inhibits prostaglandin E2-Induced uPA and MMP-9 expressions and cell migration in human LoVo colon cancer cells
Journal of Biomedical Science (2011)